Is CAR‑T cell therapy appropriate for metastatic thyroid cancer, and what are the recommended protocols, eligibility criteria, and alternative treatment options?

CAR-T Cell Therapy for Metastatic Thyroid Cancer

CAR-T cell therapy is currently NOT standard of care for metastatic thyroid cancer and should only be pursued within clinical trials, as it remains investigational with no FDA-approved products for this indication. 1

Current Treatment Landscape

The 2025 NCCN guidelines make no mention of CAR-T therapy as a recommended option for any thyroid cancer subtype 1. Instead, established systemic therapies remain the standard:

For Differentiated Thyroid Cancer (DTC):

• First-line: Lenvatinib or sorafenib for progressive, radioiodine-refractory disease
• Emerging option: Pembrolizumab added to lenvatinib
• Alternatives: Axitinib, everolimus, pazopanib, sunitinib, vandetanib
• BRAF-positive disease: Dabrafenib and vemurafenib 1

For Anaplastic Thyroid Cancer (ATC):

• Preferred: Targeted therapies (see below)
• Immunotherapy: PD-1 inhibitors (spartalizumab showed 19% ORR; pembrolizumab combined with lenvatinib showed 66% complete response in small retrospective study)
• Chemotherapy: Paclitaxel, doxorubicin monotherapy, or doxorubicin/cisplatin combination 1

Investigational CAR-T Approaches

While not clinically available, several promising CAR-T strategies are in development:

TSHR-Targeted CAR-T (Most Advanced):

The most clinically relevant approach targets thyroid-stimulating hormone receptor (TSHR). A phase I clinical trial is launching for TSHR-CAR-T cells, either alone or combined with MAPK inhibitors 2. This combination strategy addresses a critical limitation: dedifferentiated thyroid cancers downregulate TSHR expression, but MAPK inhibitors can restore it and sensitize tumors to CAR-T therapy 2. In patient-derived anaplastic thyroid cancer xenografts, this combination significantly enhanced antitumor efficacy and prolonged survival 2.

A separate TSH ligand-based CAR-T demonstrated complete tumor eradication in xenograft models with acceptable safety (only transient, reversible thyroid follicle impairment—clinically irrelevant given prior thyroidectomy in DTC patients) 3.

Other Targets Under Investigation:

• ICAM-1-targeted CAR-T: Showed profound tumor killing and long-term remission in metastatic ATC mouse models, including patient-derived tumors 4
• GFRα4-targeted CAR-T: For medullary thyroid cancer, demonstrated tumor elimination in xenograft models 5

Why CAR-T Isn't Ready for Clinical Use

Critical limitation: Current CAR-T approvals are restricted to hematologic malignancies (B-cell ALL, large B-cell lymphoma, mantle cell lymphoma, multiple myeloma) 6. Thyroid cancer represents a solid tumor with unique challenges:

1. "Cold" tumor microenvironment: Low mutational burden and high immunosuppression 7
2. Antigen heterogeneity and escape: Particularly problematic in dedifferentiated cancers 8
3. Target antigen downregulation: TSHR expression decreases with dedifferentiation 2
4. Lack of validated targets: Unlike CD19 in hematologic malignancies, no universally expressed thyroid cancer antigen exists

Practical Recommendations

For patients with metastatic thyroid cancer seeking treatment NOW:

1. Enroll in clinical trials if available (particularly TSHR-CAR-T trials launching for metastatic disease) 2

2. Use guideline-recommended therapies while awaiting CAR-T development:

   • DTC: Lenvatinib ± pembrolizumab
   • ATC: PD-1 inhibitors, targeted therapies, or chemotherapy 1

3. Consider combination immunotherapy approaches that may synergize with future CAR-T:

   • MAPK inhibitors can upregulate TSHR and improve potential CAR-T targeting 2
   • PD-1/PD-L1 inhibitors may enhance immune responses 1

Common Pitfalls to Avoid

• Do not delay standard therapy waiting for investigational CAR-T access
• Do not pursue CAR-T outside clinical trials: No safety or efficacy data in thyroid cancer patients exists
• Recognize subtype differences: CAR-T strategies differ for DTC, ATC, and medullary thyroid cancer based on target antigen expression 8, 5
• Be aware of potential toxicities: Even in approved hematologic indications, CAR-T causes cytokine release syndrome and neurotoxicity; one case report describes central hypothyroidism post-CAR-T 9

The field is rapidly evolving, with multiple promising preclinical approaches, but clinical translation remains 2-5 years away for most patients. 8, 7, 10